Emyria Ltd · ASX:EMD
Emyria — ShareCafe Small Cap "Hidden Gems" Webinar (February 2024)
17 slides from Emyria's conference presentation, Feb 2, 2024
Slide 1: ASX Announcement: Webinar Presentation
Developing new treatments for major mental health & neurological conditions ASX Announcement | 02 February 2024 Webinar Presentation Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) delivering and developing new treatments for major mental health challenges and select neurological conditions,
Slide 2: Delivering & developing new treatments to improve mental health
For personal use only (ASX:EMD) Delivering & developing new treatments to improve mental health 02 February 2024 ShareCafe Presentation
Slide 3: Disclaimer to presentation
DISCLAIMER to presentation This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any
Slide 4: Only ASX-listed company evaluating drug-assisted therapies
EMYRIA | ONLY ASX-LISTED COMPANY EVALUATING DRUG-ASSISTED THERAPIES Our goal is to become a global leader in the delivery & development of new treatments for major mental health challenges and select neurological conditions For personal use only MENTAL HEALTH DRUG-ASSISTED ACTIVE PATIENT STRONG IP F
Slide 5: Why start with drug-assisted therapies for mental health?
WHY START WITH DRUG-ASSISTED THERAPIES FOR MENTAL HEALTH? Drug-Assisted Therapies We Have A Growing Are Showing Promise & But, only Australia Has Mental Health Burden Attracting Investment 3,4,5 Rescheduled These For personal use only Treatments 6 1 in 5 Australian adults had a mental disorder last
Slide 6: Experts in therapy delivery and development will have a major advantage
TO EVALUATE THE POTENTIAL OF For personal use only INTENSIVE PSYCHOTHERAPY SUPPORTED BY MEDICATION… WE BELIEVE COMPANIES WHO ARE EXPERTS IN THERAPY DELIVERY AND DEVELOPMENT WILL HAVE A MAJOR ADVANTAGE Emyria 2024 5
Slide 7: Emyria has made significant progress last months
EMYRIA HAS MADE SIGNIFICANT PROGRESS LAST 24 MONTHS Emyria’s growth strategy SCALE VIA INNOVATION & For personal use only PARTNERSHIPS DEMONSTRATE COMMERCIAL VIABILITY BUILD CAPABILITY ✓ Fit-for-purpose facilities 1 ✓ Authorised Prescribers 5 ● Seek growth opportunities ✓ 20+ trained clinicians 2 ✓
Slide 8: Why are we starting with post-traumatic stress disorder?
WHY ARE WE STARTING WITH POST-TRAUMATIC STRESS DISORDER? PTSD is a chronic, debilitating health disorder that can occur following a traumatic event ~1,000,000 MDMA-ASSISTED EMYRIA HAS For personal use only THERAPY IS SHOWING COMMENCED AUSTRALIANS PROMISE 3 MDMA-AT TRIALS 4 6% of all adults 1 At our
Slide 9: What is MDMA-assisted therapy (MDMA-AT)?
WHAT IS MDMA-ASSISTED THERAPY (MDMA-AT)? Psychotherapy while under the influence of medical-grade MDMA to enhance the therapeutic process MDMA + PSYCHOTHERAPY Proposed Benefits with For personal use only Skilled Therapy MDMA-AT is thought to assist patients to access traumatic memories with reduced di
Slide 10: MDMA-AT showing promise for PTSD
MDMA-AT SHOWING PROMISE FOR PTSD | TWO PHASE 3 TRIALS COMPLETED 1, 2 (MAPP1 & MAPP2) Improves symptoms Improves function Key benefits after 3 treatment sessions MAPP1 MAPP1 For personal use only 86.5% of MDMA-AT participants reported improvement, compared to 69% in placebo group. Further enhancements
Slide 11: MDMA-AT costs vs standard of care
MDMA-AT COSTS 1 vs STANDARD OF CARE 2, 3 If Phase 3 clinical trial remission rates can be achieved in real world settings, MDMA-AT is cost effective for PTSD Ongoing care Typical standard of care ~ $60,000 / yr 2 For personal use only interventions 2 Neurostimulation (~$3,000) 60 Emyria’s intensive,
Slide 12: Why Emyria is starting with MDMA-assisted therapy for PTSD
WHY EMYRIA IS STARTING WITH MDMA-ASSISTED THERAPY (‘MDMA-AT’) FOR PTSD: 6% 1 PTSD affects of all Australians (~1M people) 1 PTSD NEEDS NEW TREATMENTS 60% more prevalent in first-responders 2 For personal use only 50% of patients develop treatment resistance 3 MDMA-AT SHOWS PROMISE IN 70% 2 CLINICAL T
Slide 13: Innovative, premium clinical services can do well
INNOVATIVE, PREMIUM CLINICAL SERVICES CAN DO WELL Our industry peers COMPANY SECTOR VALUATION or (REVENUES) For personal use only A US health care network of primary care USD$10.7B (acquired by CVS) 1 centers for older adults with Medicare An integrated allied healthcare A$260M (acquired by Pacific o
Slide 14: Corporate overview
EMYRIA | CORPORATE OVERVIEW Strategic investment from leading life science institutional investors ASX: EMD TRADING INFORMATION For personal use only Share Price A$0.054 1 6-Month low / high A$0.05 / 0.14 Shares Outstanding 349,226,509 Market Capitalisation ~A$20M Debt (31 Dec 2023) Nil SUBSTANTIAL
Slide 15: World-class board and management team
WORLD-CLASS BOARD AND MANAGEMENT TEAM Founded and scaled innovative clinical services; commercialised novel drug treatments For personal use only Greg Hutchinson Prof Sir John Tooke Dr Karen Smith Dr Mohit Kaushal Dr Michael Winlo Non-Executive Chairman Non-Executive Director Non-Executive Director
Slide 16: Our 12m roadmap
OUR 12m ROADMAP For personal use only # PROGRAM MILESTONE 1 MILESTONE 2 Emyria psychiatrists Provide full treatment for 1 Launch new service obtain Authorised first 20 patients Prescriber status Commence service in Treat first 20 patients in 2 Scale service nationally another AU state (via another AU
Slide 17: Contact information
CONTACT INFORMATION For personal use only Michael Winlo mwinlo@emyria.com Investors investors@emyria.com Media media@emyria.com General info@emyria.com INVESTOR HUB: https://investorhub.emyria.com/
Emyria — ShareCafe Small Cap "Hidden Gems" Webinar (February 2024) on 6ix